QT 연장 증후군(LQTS) 치료 시장 : 유형별, 치료별, 진단별 - 예측(2024-2032년)

Global Long QT Syndrome Treatment Market will witness 6.8% CAGR between 2024 and 2032, driven by increased research and development efforts by leading companies in the field. Long QT Syndrome is a cardiac disorder characterized by abnormal heart rhythms, necessitating specialized treatment to prevent life-threatening arrhythmias. Companies are investing in innovative therapies, such as new drug formulations and advanced medical devices, to address the specific needs of Long QT Syndrome patients.

For instance, in August 2023, Thryv Therapeutics Inc. announced encouraging results from the WAVE 1 Proof of Concept clinical trial assessing LQT-1213 for reducing QTcF in individuals with long QT dofetilide-induced. LQT-1213 is a powerful and selective inhibitor of Serum Glucocorticoid-Inducible Kinase 1 (SGK-1), a factor associated with QTc prolongation.

Additionally, there is a growing focus on genetic testing to identify the underlying genetic mutations associated with the condition. With advancements in understanding the molecular basis of Long QT Syndrome and the development of targeted treatments, the demand for effective therapies is rising, offering hope for improved patient outcomes.

The overall Long QT Syndrome Treatment Industry size is classified based on type, treatment, diagnosis, and region.

The long QT syndrome type 2 segment will exhibit commendable growth from 2024 to 2032. Long QT Syndrome type 2, one of the subtypes of this cardiac disorder, requires specialized treatment due to its distinct genetic and physiological characteristics. Patients with this subtype face a higher risk of life-threatening arrhythmias, necessitating targeted therapies. As research continues to advance, there is a growing understanding of the molecular mechanisms underlying Long QT Syndrome type 2, leading to the development of more effective treatments tailored to its specific needs. This has resulted in a rising demand for specialized therapies in the Long QT Syndrome treatment market.

The long QT syndrome treatment market from the genetic testing segment will register a notable CAGR from 2024 to 2032. Long QT Syndrome, a genetic heart rhythm disorder, requires personalized treatment strategies based on the specific genetic mutations involved. Genetic testing allows for the identification of these mutations, enabling targeted therapies and risk stratification for patients. With advancements in genetic testing technologies, such as next-generation sequencing, the identification of Long QT Syndrome-causing mutations has become more accessible and accurate. As a result, there is a growing demand for genetic testing in the Long QT Syndrome treatment market, facilitating more precise and tailored approaches to patient care.

Europe long QT syndrome treatment market will demonstrate a decent CAGR from 2024 to 2032. European countries are increasingly investing in advanced healthcare systems, leading to greater awareness and diagnosis of rare conditions like Long QT Syndrome. With a focus on personalized medicine, European healthcare providers are adopting innovative therapies and genetic testing to tailor treatments to individual patients. This has resulted in a growing demand for Long QT Syndrome treatments in Europe as healthcare systems strive to improve outcomes for patients with this condition.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of long QT syndrome
    • 3.2.1.2 Technological advancements in treatment modalities
    • 3.2.1.3 Advancement in genetic testing and diagnosis
    • 3.2.1.4 Growing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of surgical procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Long QT syndrome type 1
• 5.3 Long QT syndrome type 2
• 5.4 Long QT syndrome type 3
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Medication
  • 6.2.1 By drug type
    • 6.2.1.1 Potassium supplements
    • 6.2.1.2 Beta-blockers
    • 6.2.1.3 Sodium channel blockers
  • 6.2.2 By distribution channel
    • 6.2.2.1 Hospital pharmacies
    • 6.2.2.2 Retail pharmacies
    • 6.2.2.3 Online pharmacies
• 6.3 Surgical procedures
  • 6.3.1 By procedure type
    • 6.3.1.1 Implantable cardioverter-defibrillator (ICD) placement
    • 6.3.1.2 Left cardiac sympathetic denervation (LCSD)
    • 6.3.1.3 Cardiac transplantation
  • 6.3.2 By end-use
    • 6.3.2.1 Hospitals
    • 6.3.2.2 Cardiac centers
    • 6.3.2.3 Other end-users

Chapter 7 Market Estimates and Forecast, By Diagnosis 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Tests
• 7.3 Electrocardiogram
• 7.4 Genetic testing
• 7.5 Other diagnosis types

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AstraZeneca
• 9.3 Bayer AG
• 9.4 Boehringer Ingelheim
• 9.5 Boston Scientific Corporation
• 9.6 Bristol Myers Squibb
• 9.7 GSK plc
• 9.8 Medtronic Plc
• 9.9 Merck & Co., Inc.
• 9.10 Pfizer Inc.
• 9.11 Sanofi